Exhibit 99.1
Amended Loan Schedule to Secured Promissory Note dated November 10, 2022
between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC
| Date | Principal | Aggregated Principal | ||||||||||
| Original Secured Promissory Note | 11/10/2022 | $ | 2,319,279 | $ | 2,319,279 | |||||||
| Additional Loans to be included: | ||||||||||||
| Loans #1 dated 12/22/2022 through Loan #26 dated 12/12/2024 | $ | 4,625,000 | $ | 6,944,279 | ||||||||
| Loan #27 | 1/13/2025 | $ | 125,000 | $ | 7,069,279 | |||||||
| Loan #28 | 1/23/2025 | $ | 100,000 | $ | 7,169,279 | |||||||
| Loan #29 | 2/03/2025 | $ | 125,000 | $ | 7,294,279 | |||||||
| Loan #30 | 2/14/2025 | $ | 100,000 | $ | 7,394,279 | |||||||
| Loan #31 | 2/28/2025 | $ | 100,000 | $ | 7,494,279 | |||||||
| ACURA PHARMACEUTICALS, INC. | ||
| By: | /s/ Robert A. Seiser | |
| Robert A. Seiser | ||
| Senior Vice President & CFO | ||
| Date: February 28, 2025 | ||
